Stock Analiz

Brainsway Ltd. BWAY

Medical/Dental Instruments · IPO 2019 · data as of November 13, 2026

$10.11Market cap $406M
Open the interactive analysis →

Brainsway Ltd. (BWAY) is a healthcare company listed in the US with a market value of about $406M. In the twelve months to September 30, 2026 it had revenue of $65M and net income of $10M, a net margin of 15.5%.

Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: a P/E of 40.4, a price to free cash flow of 34.5, 5-year revenue growth of 12% a year, a 5-year average ROIC of -11%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 51% below the current price.

About Brainsway

Brainsway is listed in the US and classified in medical/dental instruments, IPO year 2019. Revenue went from $11M in 2017 to $52M in 2025, growth of about 21.3% a year. It was profitable in 1 of the last 9 years in our data. Its share count rose by 6% over three years (dilution for shareholders).

Score: 1.8 / 5

Value0/5
Future growth4/5
Track record1/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Positive free cash flow
  • Debt below 3 years of free cash flow

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)40.4
Forward P/E22.8
P/FCF34.5
P/S6.2
P/B4.9
EV/EBITDA41.1
PEG—
Dividend yield0.00%
FCF yield2.9%
Shareholder yield0.0%
Intrinsic value vs. price−51%

Growth and quality

Revenue growth (1 yr)29.0%
Revenue growth (5 yrs, per year)12.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-20.3%
ROIC (5-yr avg.)-11.2%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 9 years

Fiscal yearTTM202520242023202220212020201920182017
Revenue$65M$52M$41M$32M$27M$30M$22M$23M$16M$11M
Net income$10M$8M$3M-$4M-$13M-$6M-$5M-$10M-$6M-$7M
Free cash flow$12M$16M———-$1M-$4M-$11M-$6M-$4M
EPS (diluted)$0.25$0.18$0.07$-0.10$-0.33$-0.16$-0.13$-0.26$-0.16$-0.18
Net margin15.5%14.6%7.1%-13.2%-49.1%-21.8%-24.4%-44.7%-39.5%-63.3%
ROIC——1.9%-9.4%-22.1%-6.9%-19.4%-27.7%-41.3%-41.1%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 3 analysts is $19.27, 91% above the current price; targets range from $18.80 to $20.00; the consensus rating is “Strong buy”; expected EPS is $0.25 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is Brainsway’s P/E ratio?

About 40.4, based on the last twelve months of diluted earnings per share (forward P/E about 22.8).

Is Brainsway stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 51% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Brainsway pay a dividend?

Not currently.

Is Brainsway a good stock to buy?

We do not give buy or sell advice. Brainsway scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.